
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. presents a compelling investment opportunity, as its current valuation reflects a balance between high risks and substantial upside potential. The company is focusing on early-stage commercialization of its innovative medical technologies, with anticipated significant growth in revenue projected for 2025 and 2026. Furthermore, a net present value (NPV) analysis suggests an upward adjustment in the company's valuation, indicating that it remains an attractive investment in the medical technology sector.
Bears say
PAVmed Inc. reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), indicating a weaker performance than anticipated as it fell below both internal and consensus estimates. The company also experienced a decline in EsoGuard test volumes, processing only 2,756 tests in Q2, a decrease from previous quarters, highlighting potential challenges in demand for its diagnostics products. Additionally, several risks have been identified that could hinder PAVmed's operations, including liquidity concerns, regulatory hurdles, competition, and shifts in healthcare priorities, contributing to the negative outlook on the company’s financial health.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares